Retatrutide for Advanced Weight Management — Weight & Metabolism
Triple agonist (GIP/GLP-1/Glucagon) showing exceptional weight loss results in clinical trials.
Overview
Retatrutide is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors. NEJM Phase 2 RCT (n=338, 48 weeks) showed 24.2% weight loss with 12mg dose—superior to all approved obesity medications. Lancet Phase 2 trial (n=281) demonstrated 16.9% weight loss plus 2.0% HbA1c reduction in type 2 diabetes. Nature Medicine substudy (n=98) achieved 82% liver fat reduction in MASLD patients. Meta-analyses (n=640 and n=878) confirm consistent efficacy across obesity, diabetes, and fatty liver disease with acceptable GI side effects. Phase 3 TRIUMPH trials ongoing; FDA approval expected mid-2026.
Indications
- Significant obesity requiring aggressive weight management
- Metabolic syndrome with multiple components
Mechanism of Action
Multiple metabolic pathways dysregulated requiring comprehensive therapeutic intervention beyond single hormone targeting
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Retatrutide | 2 mg | Once weekly | Starting dose, GI tolerance assessment |
| Retatrutide | 4 mg | Once weekly | First therapeutic dose, early weight loss |
| Retatrutide | 6 mg | Once weekly | Enhanced efficacy, 12-15% weight loss |
| Retatrutide | 8-12 mg | Once weekly | Maximum dose, up to 24% weight loss at 48 weeks |
Evidence Grade
GRADE B
Safety & Contraindications
- Investigational agent - not yet FDA approved
- Similar side effect profile to GLP-1 agonists (GI symptoms)
- Requires medical supervision